Mipomersen sodium: A new option for the treatment of familial hypercholesterolemia

Drugs of Today

Volumn 47, Issue 12, 2011, Pages 891-901

  Haddley, K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MIPOMERSEN; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AORTA ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FATTY LIVER; FLU LIKE FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPERLIPIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APOLIPOPROTEINS B; CHOLESTEROL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPOLIPIDEMIC AGENTS; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84856582157     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.12.1722069     Document Type: Review

References (70)

1. Goldstein, J.L., Hobbs, H.H., Brown, M.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.). The Metabolic and Molecular Basis of Inherited Disease. 8th edition. McGraw Hill: New York 2001, 2863-913.
2. Neaton, J.D., Wentworth, D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099white men. Multiple Risk Factor Intervention Trial Research Group. Arch Int Med 1992, 152(1): 56-64.
3. Innerarity, T.L., Mahley, R.W., Weisgraber, K.H., et al. Familial defective apolipoprotein B-100: A mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990, 31(8): 1337-49. (Pubitemid 20261898)
4. Myant, N.B. Familial defective apolipoprotein B-100: A review, including some comparisons with familial hypercholesterolemia. Atherosclerosis 1993, 104(1-2): 1-18. (Pubitemid 24035628)
5. Norman, D., Sun, X-M., Bourbon, B.L. et al. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J Clin Invest 1999, 104(5): 619-28.
6. Rader, D.J., Cohen, J., Hobbs, H.H. Monogenic hypercholesterolemia: New insights in pathogenesis and treatment. J Clin Invest 2003, 111(12): 1795-803. (Pubitemid 38057721)
7. Davis, R., Sinensky, M., Junker, L.H. Regulation of cholesterol synthesis and the potential for its pharmacologic manipulation. Pharmacol Ther 1989, 43: 221-36. (Pubitemid 19201284)
8. Visser, M.E., Kastelein, J.J.P., Stroes, E.S.G. Apolipoprotein B synthesis inhibition: Results from clinical trials. Curr Opin Lipidol 2010, 21(4): 319-23.
9. Kastelein, J.P, Wedel, M.K., Baker, B.F. et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114(16): 1729-35. (Pubitemid 44607121)
10. Linton, M.F., Farese, R.V., Young, S.G. Familial hypobetalipoproteinemia. J Lipid Res 1993, 34(4): 521-41. (Pubitemid 23118753)
11. Neuman, R.J., Yuan, D.S., Gerhard, K.Y. et al. Replication of linkage of familial hypobetalipoproteinemia to chromosome 3p in six kindreds. J Lipid Res 2002, 43(3): 407-15. (Pubitemid 34252271)
12. Targui, P., Lonardo, C., Gabelli, I.F. et al. Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene. J Lipid Res 2001, 42(10): 1552-61.
13. Sun, X.M., Patal, D.D., Webb, J.C. et al. Familial hypercholesterolemia in China. Identification of mutations in the LDL-receptor gene that result in a receptor negative phenotype. Arterioscler Thromb Vasc Biol 1994, 14(1): 85-94.
14. Wiviott, S. D., Cannon, C.P. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006, 17(6): 626-30. (Pubitemid 44729954)
15. Versmissen, J., Oosterveer, D.M., Yazdanpanah, M. et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. Br Med J 2008, 337: a2423.
16. Law, M. Rudnicka, A.R. Statin safety: A systematic review. Am J Cardiol 2006, 97(8A): 52C-60C.
17. Davidson, M.H. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009, 11(1): 67-70.
18. Buchwald, H., Rudser, K.D., Williams, S.E., Michalek, V.N., Vagasky, J., Connett, J.E. Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias. Ann Surg 2010, 251(6):1034-40.
19. Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003, 270(8): 1628-44. (Pubitemid 36532522)
20. Crooke, R.M. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Exp Opin Biol Ther 2005, 5(7): 907-17. (Pubitemid 41032848)
21. Altmann, K.-H., Fabbro, D., Dean, N.M. et al. Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal transduction inhibitors. Biochem Soc Trans 1996, 24(3): 630-7. (Pubitemid 26306268)
22. Baker, B.F., Lot, S.S., Condon, T.P. et al. 2′-O-(2-Methoxy)ethyl- modified antiintercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997, 272(18): 11994-2000. (Pubitemid 27202775)
23. McKay, R.A., Miraglia, L.J., Cummins, L.L. et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 1999, 274(3): 1715-22.
24. El Harchaoui, K., Akdim, F., Stroes, E.S., Trip, M.D., Kastelein, J.J. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins. Am J Cardiovasc Drugs 2008, 8(4): 233-42.
25. Genzyme and Isis announce submission of European marketing authorization application for mipomersen (ynamro(R)) [news release]. Genzyme Corporation, July 28, 2011. http://www.businesswire.com/news/genzyme/20110727007161/en. Accessed November 30, 2011.
26. Graham, M.J., Lemonidis, K.M., Whipple, C., Petinos, N., Crooke, R.M. Inhibition of human apoB-100 in transgenic mice. Circulation 2003, 108(17, Suppl. 4): Abst 836.
27. Geary, R., Yu, R., Kim, T.-W., Levin, A., Dokka, S., Tillman, L., Hardee, G. Pharmacokinetics and tolerability of daily oral antisense oligonucleotide, ISIS301212, in mice and dog for 13 weeks. Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 6-10, Nashville) 2005, Abst T3305.
28. Geary, R.S., Kuller, A., Riley-McMullen, G.C., Watanabe, T.A. In vitro protein binding evaluation of an antisense oligonucleotides, mipomersen, targeting human apolipoprotein B. AAPS Natl Biotech Conf (June 22-25, Toronto) 2008, Abst M1002.
29. Baek, M-S., Yu, R.Z., Geary, R.S. In vitro metabolism of mipomersen (ISIS301012), a second-generation antisense oligonucleotides targeting human apolipoprotein B-100.Annu Meet Am Assoc Pharm Sci (AAPS) (Nov 16-20, Atlanta) 2008, Abst W5271.
30. Baek, M.-S., Yu, R.Z., Gaus, H. et al. In vitro metabolic studies and metabolism of 2′-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides 2010, 20(6): 309-16.
31. Yu, R.Z., Kim, T.W., Hong, A. et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007, 35(3): 460-8. (Pubitemid 46333910)
32. Yu, R.Z., Lemonidis, K.M, Graham, M.J. et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009, 77(5): 910.
33. Geary, R.S., Watanabe, T.A., Troung, L. et al. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rat. J Pharmacol Exp Ther 2001, 296(3): 890-7. (Pubitemid 32187362)
34. Yu, R.Z, Geary, R.S., Monteith, D.K. et al. Tissue disposition of 2′-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharmacol Sci 2004, 93(1): 48-59. (Pubitemid 38081813)
35. Kastelein, J.P., Bradley, J., Chuang, E. et al. Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia. Atherosclerosis Suppl [XIV Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-P16:268
36. Kastelein, J.P., Wedel, M.K., Baker, B. et al. Significant reduction of small dense LDL-cholesterol concentrations in healthy volunteers by antisense inhibition of apolipoprotein B. Atherosclerosis Suppl [XIV Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:6.
37. Kastelein, J., Akdim, F., Trip, M. ISIS301012, an antisense inhibitor of apolipoprotein B, produces significant additional reduction of low-density lipoprotein cholesterol and apolipoprotein B in hypercholesterolemic subjects on statins not meeting target. J Am Coll Cardiol [56th Annu Sci Sess Am Coll Cardiol (ACC) (Mar 24-27, New Orleans) 2007] 2007, 49(9, Suppl. A): Abst 820-7.
38. Bradley, J., Crooke, R., Graham, M., Wedel, M. Small, dense, LDL particle concentration is significantly reduced after treatment with an antisense inhibitor of apoB in healthy volunteers. Circulation 2005, 112(17, Suppl. 2): Abst 727.
39. Bradley, J., Crooke, R., Kjems, L.L. et al. Hypolipidemic effects of a novel inhibitor of human apoB-100 in humans. 65th Annu Meet Sci Sess Am Diabetes Assoc (ADA) (June 10-14, San Diego) 2005, Abst 977-P.
40. Bradley, J.D., Graham, M., Henry, S., Kim, T-M., Crooke, R., Yu, R., de Haan, H. Evaluation of ISIS 301012, an antisense inhibitor to human apoB 100, in healthy volunteers. 15th Int Symp Drugs Affect Lipid Metab (Oct 24-27, Venice) 2004, 37.
41. Mullick, A.E., Graham, M.J., Crooke, R.M. et al. Antisense inhibition of apolipoprotein B-ameliorated diet-induced hypercholesterolemia and reduced atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2008, 28(6): Abst P345.
42. Merki, E., Graham, M.J., Mullick, A.E. et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008, 118(7): 743-53.
43. Crooke, R.M., Graham, M.J., Lemonidis, K.M. et al. An apolipoprotein B antisense oligonucleotides lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005, 46(5): 872-84.
44. Chuang, E., Lemonidis, K.M., Whipple, M.J. et al. A human apolipoprotein B antisense inhibitor reduces aortic sinus plaque volume in LDL receptor deficient, human apolipoprotein B-100 transgenic mice. Atherosclerosis Suppl [XIV Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-W49:5.
45. Geary, R., Yu, R., Bradley, J., et al. Lack of pharmacokinetic interactions of an antisense oligonucleotides targeting human apoB, when coadministered with simvastatin and ezetimibe, in man. Atherosclerosis Suppl [XIV Int Symp Atherosclerosis (June 18-22, Rome) 2006] 2006, 7(3): Abst Th-P16:258.
46. Yu, R.Z., Geary, R.S., Flaim, J.D. et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2′-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009, 48(1): 39-50.
47. Adkim, F., Stroes, E.S.G., Sijbrands, E.J.G. et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010, 55(15): 1611-8.
48. Stein, E. High low-density lipoprotein cholesterol on three drugs. 56th Annu Sci Sess Am Coll Cardiol (ACC) (Mar 24-27, New Orleans) 2007, Presentation 603-8.
49. Stein, E., Wedel, M., Bradley, J. Statin-like dose-dependent reductions in LDL cholesterol and apolipoprotein B with ISIS 301012, an antisense inhibitor of apolipoprotein B, in subjects with polygenic hypercholesterolemia. J Am Coll Cardiol [56th Annu Sci Sess Am Coll Cardiol (ACC) (Mar 24-27, New Orleans) 2007] 2007, 49(9, Suppl. A): Abst 1206-278.
50. Dose-escalating safety study in subjects on stable statin therapy (NCT00231569). ClinicalTrials.gov Web site. Accessed December 1, 2011.
51. Dose-escalating safety study of ISIS 301012 in homozygous familial hypercholesterolemia subjects on lipid lowering therapy (NCT00280995). ClinicalTrials.gov Web site. Accessed December 1, 2011.
52. Safety and tolerability of varying load and dose of ISIS 301012 in people with elevated LDL-cholesterol levels (NCT00216463). ClinicalTrials.gov Web site. Accessed December 1, 2011.
53. Safety and efficacy study of ISIS 301012 (mipomersen) administration in high risk statin intolerant subjects (NCT00707746). ClinicalTrials.gov Web site. Accessed December 1, 2011.
54. Study of ISIS 301012 in heterozygous familial hypercholesterolemia subjects on lipid lowering therapy (NCT 00281008). ClinicalTrials.gov Web site. Accessed December 1, 2011.
55. Adkim, F., Visser, M.E., Tribble, D.L. et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010, 105(10): 1413-9.
56. Open label extension of ISIS 301012 (mipomersen) to treat familial hypercholesterolemia (NCT00477594). ClinicalTrials.gov Web site. Accessed December 1, 2011.
57. Isis Pharmaceuticals updates its positive phase 2 data for ISIS 301012 in familial hypercholesterolemia patients [news release]. Isis Pharmaceuticals, May 17, 2007.
58. Raal, F.J., Santos, R.D., Blom, D.J. et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010, 375(9719): 998-1006.
59. Patel, N. and Hegele, R.A. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Exp Opin Pharmacother 2010, 11(15): 2569-72.
60. Study to assess the safety and efficacy of ISIS 301012 (mipomersen) in homozygous familial hypercholesterolemia (NCT00607373). ClinicalTrials.gov Web site. Accessed December 1, 2011.
61. Mipomersen phase 3 study in patients with heterozygous familial hypercholesterolemia meets primary endpoint [news release]. Genzyme Corporation, February 10, 2010. http://www.businesswire.com/news/genzyme/20100210005377/en. Accessed November 30, 2011.
62. Stein, E., Dufour, R., Gagne, C. et al. A randomized, doubleblind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J [ESC Congr (Aug 28-Sept 1, Stockholm) 2010] 2010, 31(Suppl.): Abst 5036.
63. Data from two mipomersen phase 3 trials presented at ACC [news release]. Genzyme Corporation, April 5, 2011. http://www.businesswire.com/news/genzyme/ 20110405006275/en. Accessed November 30, 2011.
64. Tardif, J.C., McGowan, M., Ceska, R. et al. Apolipoprotein B synthesis inhibition by Mipomersen reduces low-density lipoprotein cholesterol when added to maximally tolerated lipid-lowering medication in patients with severe heterozygous hypercholesterolemia. 60th Annu Sci Sess Am Coll Cardiol (ACC) (April 3-5, New Orleans) 2011, Abst 920-3.
65. Cromwell, W.C., Thomas, G.S., Boltje, I., Chin, W., Davidson, M. Safety and efficacy of mipomersen administered as addon therapy in patients with hypercholesterolemia and high cardiovascular risk. 60th Annu Sci Sess Am Coll Cardiol (ACC) (April 3-5, New Orleans) 2011, Abst 1011-304.
66. Visser, M.E., Akdim, F., Tribble, D.L. et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010, 51(5): 1057-62.
67. Feingold, K.R. Does inhibition of apolipoprotein B synthesis produce foie gras? J Lipid Res 2010, 51(5): 877-8.
68. Kling, J. Safety signal dampens reception for mipomersen antisense. Nat Biotechnol 2010, 28(4): 295-7.
69. An open-label extension study to assess the long-term safety and efficacy of ISIS 301012 (mipomersen) in patients with familial hypercholesterolemia or severe hypercholesterolemia (NCT00694109). ClinicalTrials.gov Web site. Accessed December 1, 2011.
70. A study to evaluate the effect of mipomersen on cardiac repolarization conducted in healthy subjects (NCT01090661). ClinicalTrials.gov Web site. Accessed December 1, 2011.